Pfizer (NYSE:PFE) Trading Down 2.4% – Here’s Why

Pfizer Inc. (NYSE:PFE) shares dropped 2.4% on Tuesday . The stock traded as low as $27.72 and last traded at $27.78. Approximately 31,717,839 shares changed hands during trading, a decline of 24% from the average daily volume of 41,495,664 shares. The stock had previously closed at $28.45.

Analysts Set New Price Targets

Several equities analysts have recently commented on PFE shares. UBS Group restated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research report on Wednesday, May 27th. BMO Capital Markets cut their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. HSBC boosted their price target on Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Finally, Bank of America reduced their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus price target of $28.39.

Pfizer Stock Down 0.5%

The stock has a market capitalization of $157.50 billion, a price-to-earnings ratio of 36.36, a price-to-earnings-growth ratio of 1.87 and a beta of 0.34. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The stock has a 50 day moving average price of $26.21 and a 200 day moving average price of $26.35.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the firm posted $0.78 earnings per share. The firm’s revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 1st. Investors of record on Friday, July 24th were given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.2%. The ex-dividend date of this dividend was Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is currently 226.32%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of PFE. California State Teachers Retirement System lifted its position in shares of Pfizer by 2,320.6% during the 2nd quarter. California State Teachers Retirement System now owns 217,981,455 shares of the biopharmaceutical company’s stock valued at $5,248,993,000 after acquiring an additional 208,976,273 shares during the period. Norges Bank acquired a new stake in Pfizer in the fourth quarter worth $1,830,986,000. Bank of America Corp DE bought a new stake in Pfizer in the second quarter valued at $1,049,602,000. BlackRock Inc. grew its stake in shares of Pfizer by 6.3% in the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after buying an additional 31,412,883 shares during the period. Finally, Morgan Stanley increased its position in Pfizer by 19.2% in the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after buying an additional 14,342,946 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer’s products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.